Singapore markets closed

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3000+0.2000 (+6.45%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 140.04M
Enterprise value -80.17M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.73
Price/book (mrq)0.66
Enterprise value/revenue -1.57
Enterprise value/EBITDA 0.70

Trading information

Stock price history

Beta (5Y monthly) 0.56
52-week change 3-66.70%
S&P500 52-week change 323.57%
52-week high 313.8500
52-week low 32.9800
50-day moving average 34.7486
200-day moving average 36.8431

Share statistics

Avg vol (3-month) 3126.82k
Avg vol (10-day) 3134.35k
Shares outstanding 542.45M
Implied shares outstanding 642.45M
Float 815.09M
% held by insiders 11.02%
% held by institutions 193.69%
Shares short (15 Apr 2024) 4608.26k
Short ratio (15 Apr 2024) 45.8
Short % of float (15 Apr 2024) 42.43%
Short % of shares outstanding (15 Apr 2024) 41.44%
Shares short (prior month 15 Mar 2024) 4658.55k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -183.43%
Operating margin (ttm)-236.58%

Management effectiveness

Return on assets (ttm)-23.51%
Return on equity (ttm)-38.16%

Income statement

Revenue (ttm)51.13M
Revenue per share (ttm)1.22
Quarterly revenue growth (yoy)-28.30%
Gross profit (ttm)N/A
EBITDA -114.27M
Net income avi to common (ttm)-93.8M
Diluted EPS (ttm)-2.2300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)223.63M
Total cash per share (mrq)5.3
Total debt (mrq)3.41M
Total debt/equity (mrq)1.61%
Current ratio (mrq)6.24
Book value per share (mrq)5.03

Cash flow statement

Operating cash flow (ttm)-127.16M
Levered free cash flow (ttm)-97.36M